



Caribou Biosciences Appoints Scott Braunstein, M.D. to Board of Directors

June 22, 2021

BERKELEY, CA – June 22, 2021 – Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that it has appointed Scott Braunstein, M.D. to its board of directors. Dr. Braunstein, an accomplished leader with over 20 years of industry experience, has expertise and experience in governing, leading, and investing in biopharmaceutical companies.

"It is a great privilege to welcome Scott to our board of directors," said Rachel Haurwitz, Ph.D., president and chief executive officer of Caribou. "We believe his extensive experience in financing and executing on the development of novel therapeutics will be especially valuable to us as we advance our chRDNA-edited allogeneic cell therapies and continue to build the company."

"As a pioneer in CRISPR genome editing, Caribou has a rich pipeline of promising next-generation cancer-targeted cell therapies that are designed to enhance persistence and unlock the broad potential of allogeneic cell therapies," said Dr. Braunstein. "I look forward to collaborating with the team as they progress in the clinic and pursue their goals to transform the landscape of genome-edited cell therapies and improve outcomes for patients."

Dr. Braunstein currently serves as chief executive officer and on the board of directors of Marinus Pharmaceuticals, a company dedicated to the development of innovative therapeutics that treat rare seizure disorders. He has held the role of operating partner at Aisling Capital since 2015. Prior to joining Marinus Pharmaceuticals, Dr. Braunstein previously served as chief strategy officer and chief operating officer at Pacira Pharmaceuticals, Inc. Earlier in his career, Dr. Braunstein served as a healthcare portfolio manager at Everpoint Asset Management and spent 12 years with J.P. Morgan Asset Management as a healthcare analyst and managing director on the U.S. equity team and as portfolio manager of the J.P. Morgan Global Healthcare Fund. Dr. Braunstein also serves as a board member of Trevena, Inc. and Constellation Pharmaceuticals, which recently received a tender offer from MorphoSys AG to acquire all of the outstanding shares of Constellation's common stock in cash. He previously served as a board member of Ziopharm Oncology, Inc., Esperion Therapeutics, Inc., and Protara Therapeutics, Inc. Dr. Braunstein began his career as a physician at the Summit Medical Group and as assistant clinical professor at Albert Einstein College of Medicine and Columbia University Medical Center. He received his medical degree from the Albert Einstein College of Medicine and his B.S. from Cornell University.

About Caribou's Novel Next-Generation CRISPR Platform

CRISPR genome-editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Type II CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to editing at the targeted genomic site. CRISPR systems occasionally edit unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed chRDNAs (pronounced "chardonnays"), RNA-DNA hybrid guides that direct substantially more precise genome editing, including multiplex editing and gene insertion, than all-RNA guides. Caribou is deploying the power of chRDNAs to develop CRISPR-edited therapies by guiding cellular editing with the highest level of fidelity.

About Caribou Biosciences, Inc.

Caribou is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying the company's proprietary chRDNA technology toward the development of next-generation, genome-edited cell therapies. The company is developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of both hematologic malignancies and solid tumors for both clinically evaluated targets as well as new targets.

For more information about Caribou, visit www.cariboubio.com and follow the company @CaribouBio.

"Caribou Biosciences" and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.

Caribou Biosciences Media Contact:

Greg Kelley
Ogilvy
gregory.kelley@ogilvy.com
617-461-4023

Caribou Biosciences Investor Relations Contact:

Elizabeth Wolffe, Ph.D. and Sylvia Wheeler
Wheelhouse LSA
lwolffe@wheelhousesa.com
swheeler@wheelhousesa.com